
Mirum Pharmaceuticals, Inc.: A US-based biopharmaceutical company specializing in cholestatic liver disease therapies.
Mirum Pharmaceuticals, Inc. is a US-based biopharmaceutical company dedicated to developing therapies for cholestatic liver diseases. The company's mission is to address the unmet needs of patients with rare liver conditions by creating transformative treatments. Mirum Pharmaceuticals focuses on providing innovative solutions that significantly improve the quality of life for patients and their families.
Mirum Pharmaceuticals has made significant strides in the field of liver disease treatment, earning recognition for its commitment to scientific innovation and patient care. The company’s therapies have shown promise in clinical trials, positioning Mirum as a leader in the biopharmaceutical industry. Their efforts have had a profound impact on the lives of those affected by cholestatic liver diseases, underscoring the company's dedication to making a remarkable difference.

Intercept Pharmaceuticals

Mirata Pharmaceuticals

Catalyst Pharmaceuticals
catalystpharma.com

Bayer Pharmaceuticals
bayer.com

Lumos Pharma
lumos-pharma.com
Mira Oncology
Assertio Holdings

PTC Therapeutics
ptcbio.com
Bristol Myers Squibb
bms.com

Marius Pharmaceuticals
mariuspharma.com

Galmed Pharmaceuticals
galmedpharma.com

Karyopharm Therapeutics
karyopharm.com

Marinus Pharmaceuticals
marinuspharma.com

Enanta Pharmaceuticals
enanta.com

Auxilius Pharma
auxiliuspharma.com
Companies similar to Mirum Pharmaceuticals include Intercept Pharmaceuticals, Mirata Pharmaceuticals, Catalyst Pharmaceuticals and Bayer Pharmaceuticals.
Mirum Pharmaceuticals was founded in 2018.
Mirum Pharmaceuticals' headquarters is located in Foster City, CA, US.
Mirum Pharmaceuticals' most recent funding round was for $275M (USD) in April 2023.
As of Apr 13, 2023, Mirum Pharmaceuticals has raised a total of $497M (USD).
Mirum Pharmaceuticals has 196 employees as of Feb 6, 2024.